REsect is a retrospective analysis of the SIRFLOX study patient cohort. The extensive radiological database of SIRFLOX was evaluated by a panel of 14 HPB (Hepato-Pancreato-Biliary) surgeons from leading medical centres in Belgium, France, Germany, Italy, The Netherlands, Spain, the UK and the USA to compare potential liver resectability at baseline and follow-up.
The results of REsect were presented at the 12th International Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), May 2017.
REsect demonstrated that the addition of SIR-Spheres Y-90 resin microspheres to FOLFOX (± bev)-based chemotherapy significantly increased the proportion of patients determined to have resectable liver metastases compared with chemo alone (38.11% in the SIRT + chemotherapy arm vs. 28.95% in the chemotherapy alone arm; p<0.0001).
A team of hepatobiliary surgeons performed independent analyses of baseline and follow-up scans from 472 patients. Five surgeons assessed at random 100 patients and the analysis of the remaining scans was conducted in groups of 22–25 cases by three surgeons randomly selected from the nine other members of the panel. The reviewers were blinded to patient identifiers, visit (baseline or follow-up), treatment and clinical information, as well as to the other reviewers’ assessments. A patient was deemed resectable or unresectable by majority agreement (≥3 of 5 surgeons or ≥2 of 3 surgeons).
A total of 472 patients with similar baseline characteristics were evaluable (mFOLFOX n=228; mFOLFOX + SIRT n = 244).
Eligibility for Resection
REsect showed increased eligibility for liver resection following SIR-Spheres Y-90 resin microspheres.
bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)
Garlipp B et al. E-AHPBA 2017; Abs. FP 15.08.